Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

Phase 1DMR-001Positive

AI Analysis

Summary

Damora Therapeutics has initiated the Phase 1/1b CLARITY-101 clinical trial evaluating DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.

Clinical Trial Data

Phase

Phase 1/1b

Importance:5/10

Sentiment:

0.50

clinical_trial_initiationphase_1rare_diseasehematology

Related Companies

$DMRA

Read the original article

Published by yahoo_finance on August 5, 2026 12:00 PM

Read Original